[{"orgOrder":0,"company":"University of Rochester","sponsor":"National Institute of Neurological Disorders and Stroke | Michael J. Fox Foundation | Parkinson Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Isradipine","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Rochester \/ National Institute of Neurological Disorders and Stroke | Michael J. Fox Foundation | Parkinson Study Group","highestDevelopmentStatusID":"10","companyTruncated":"University of Rochester \/ National Institute of Neurological Disorders and Stroke | Michael J. Fox Foundation | Parkinson Study Group"}]

Find Clinical Drug Pipeline Developments & Deals for Prestwick3_001021

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Rochester

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Rochester

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Isradipine

                          Therapeutic Area : Neurology

                          Study Phase : Phase III

                          Sponsor : National Institute of Neurological Disorders and Stroke | Michael J. Fox Foundation | Parkinson Study Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Isradipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 20, 2014

                          Lead Product(s) : Isradipine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : National Institute of Neurological Disorders and Stroke | Michael J. Fox Foundation | Parkinson Study Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank